4-butyrolactone has been researched along with pyrazolanthrone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Q; Qiu, TQ; Yang, H | 1 |
| Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Huang, SY; Lin, SZ; Pang, CY; Wang, MJ; Yang, HH | 1 |
2 other study(ies) available for 4-butyrolactone and pyrazolanthrone
| Article | Year |
|---|---|
Ligustilide inhibits vascular smooth muscle cells proliferation.
Topics: 4-Butyrolactone; Animals; Anthracenes; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Enzyme Activation; Flavonoids; Imidazoles; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphorylation; Pyridines; Rats; Rats, Wistar; Reactive Oxygen Species; Retinoblastoma Protein | 2006 |
Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells.
Topics: 4-Butyrolactone; Anthracenes; Benzodioxoles; Blotting, Western; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Growth Differentiation Factor 15; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Signal Transduction; Tumor Suppressor Protein p53 | 2011 |